



1 4 September 2020

2
3

4 COVID-19 vaccines in the EU

5 **Basic facts**

6

7 ***Why are vaccines to prevent COVID-19 urgently needed?***

- 8 • COVID-19 vaccines are medicines that aim to prevent disease caused by the novel coronavirus
9 SARS-CoV-2 by triggering an immune response.
- 10 • The current COVID-19 pandemic is a global crisis, with devastating health, social and economic
11 impact.
- 12 • COVID-19 can cause severe disease and death with yet unknown long-term consequences in
13 people of all ages, including in otherwise healthy people.
- 14 • Safe and effective vaccines for COVID-19 are needed to protect individuals from becoming ill,
15 especially healthcare professionals and vulnerable populations, such as older people or those with
16 chronic diseases.

17 ***Is there a vaccine to protect against COVID-19?***

- 18 • There are no vaccines approved yet in the EU to prevent or treat any of the human coronavirus
19 infections, including those causing the common colds or more serious conditions.
- 20 • Due to the urgency posed by the pandemic, efforts are ongoing to develop and study COVID-19
21 vaccines in order to approve and make them available as soon as possible.
- 22 • It is not currently known what level of protection can be reached with the vaccines in development.
23 Reasonably effective vaccines, together with other public health measures and therapeutic
24 treatments, will be a key component in overcoming COVID-19.
- 25 • Vaccines work by preparing a person's immune system (the body's natural defences) to recognise
26 and defend itself against a specific disease. Most research on COVID-19 vaccines involves
27 generating responses to all or part of a protein (spike protein, or protein S) that is unique to the
28 virus that causes COVID-19. When a person receives the vaccine, it will trigger an immune
29 response. If the person is infected by the virus later on, the immune system recognises the virus
30 and, because it is already prepared to attack the virus, protects the person from COVID-19.

31
32

What process and methods are being used to develop and approve COVID-19 vaccines?

- 33 • COVID-19 vaccines are being developed following the same legal requirements for pharmaceutical
34 quality, safety and efficacy as other medicines.
- 35 • Like all medicines, COVID-19 vaccines' effects are first tested in laboratory, including in animals,
36 and then vaccines are tested in human volunteers.
- 37 • Before approval, all vaccines in the EU are evaluated against the same high standards as any other
38 medicine.
- 39 • What is different for COVID-19 vaccines is that speed of development and potential approval is
40 much faster due to the public health emergency.
- 41 • EMA has put in place a dedicated expert task force and rapid review procedures to evaluate high-
42 quality applications from companies in the shortest possible timeframes, while ensuring robust
43 scientific opinions.
- 44 • The European Commission will make use of all existing flexibilities to accelerate the approval of
45 any potential vaccines for use across the EU, but this will only be possible if EMA receives sound
46 scientific evidence that allows establishing that vaccines' benefits are greater than any risks.
- 47 • Vaccine manufacturers and academics are using established production systems currently used for
48 safe and effective vaccines. In addition, they are continuously researching novel approaches to
49 producing and developing vaccines, and some of the advances made to date are also being applied
50 to developing vaccines for COVID-19.
- 51 • Some vaccines for COVID-19 are being developed using novel methods that are expected to
52 increase the volume and speed of production compared to other types of vaccines, enhance
53 product stability and bring about strong immune responses.
- 54 • Other vaccines are being developed using existing methods. These are already used in vaccines for
55 other diseases, which means it could be easier to use existing production facilities to produce
56 COVID-19 vaccines at a large scale than for newer vaccine types.

57

Why did development only start after the pandemic was declared?

- 58 • Vaccines can only be developed when the infectious agent is known. Because SARS-CoV-2 is a new
59 virus that had not been seen before, development of a vaccine to protect against COVID-19 could
60 only be started once the virus emerged and its genetic make-up had been analysed. However,
61 vaccine development builds on experience and technologies used for other vaccines.

62

When will the vaccines be approved?

- 63 • At present it is not known whether COVID-19 vaccines will be approved or how long this will take,
64 as timelines are difficult to predict.
- 65 • Vaccine development is progressing, and, in a best-case scenario, the Agency would receive clinical
66 data on the most advanced vaccines in development towards the end of 2020.
- 67 • Regulators would then carry out a scientific evaluation of the vaccine's safety, efficacy and quality,
68 before concluding on whether there is sound scientific evidence supporting approval.

- 69 • If the scientific evidence supports a positive benefit-risk assessment for any of the vaccines, the
70 European Commission will grant a marketing authorisation valid across the EU in the shortest
71 possible timelines.
- 72 • For evaluation of other vaccines currently at earlier development stages, this would likely take
73 place throughout 2021 and beyond.

74 ***What type and amount of data is needed for approving a safe and***
75 ***effective vaccine?***

- 76 • COVID-19 vaccine developers need to submit specific data on their vaccine. EMA then carries out a
77 thorough assessment of these data to reach a scientific opinion on whether the vaccine is safe,
78 efficacious and of good quality and is therefore suitable to vaccinate people.
- 79 • The data should show the vaccine's efficacy in protecting against COVID-19 (how well the vaccine
80 works in clinical settings) and its safety.
- 81 • Efficacy is measured by looking at how well the vaccine works in the study, for example how well
82 the vaccine prevents symptomatic disease. These efficacy measures are called 'endpoints'. Efficacy
83 endpoints are required because COVID-19 is a new disease and because there are no known
84 indicators (such as the levels of antibodies in the blood) that can predict protection.
- 85 • The safety requirements for COVID-19 vaccines are the same as for any other vaccine in the EU
86 and will not be lowered in the context of the pandemic.
- 87 • The data submitted in a marketing authorisation application for a COVID-19 vaccine must include
88 information on:
- 89 • the group of people to be given the vaccine;
 - 90 • its pharmaceutical quality, including information on the identity and purity of the vaccine
91 components and its content and biological activity (potency);
 - 92 • data on each step of manufacturing and on the controls used to ensure that each batch of
93 vaccine is consistently of good quality;
 - 94 • compliance with international requirements for laboratory testing, vaccine manufacture and
95 conduct of clinical trials ('[good laboratory practice](#)', '[good clinical practice](#)' and '[good](#)
96 [manufacturing practice](#)');
 - 97 • types of immune responses induced by the vaccine;
 - 98 • the effects observed in the groups of people to be given the vaccine;
 - 99 • the vaccine's side effects observed in vaccinees, including if there are any data in special
100 populations such as older people or pregnant women;
 - 101 • information intended to be gathered from follow-up studies after authorisation (e.g. long-
102 term safety data or long-term immunity);
 - 103 • prescribing information to be provided to patients and healthcare professionals (i.e. the
104 summary or product characteristics or SmPC, labelling and package leaflet), which is drafted
105 by the developer and reviewed and agreed by EMA's scientific committees;
 - 106 • the way risks will be managed and monitored once the vaccine is authorised; the risk
107 management plan (RMP), a document with information about any possible (known or
108 potential) safety concerns with the vaccine, the way risks will be managed and monitored

109 once the vaccine is authorised and what information is intended to be gathered from follow-
110 up studies. The RMP is evaluated by EMA's safety committee, PRAC.

111 ***How long will immunity from a vaccine last?***

112 • Currently, because the virus is so novel, there is not enough knowledge on how long the immunity
113 conferred by the vaccines will last after vaccination, or whether there will be a need for periodic
114 booster doses.

115 • Data from immunogenicity and efficacy studies in the long term will inform future vaccination
116 strategies.

117 • Vaccination policies are not decided by EMA but by public health agencies in EU member states.

118 ***Will vaccines protect vaccinated people if the virus mutates?***

119 • Typically, viruses mutate (the genetic material in the virus changes); this happens at different
120 rates for different viruses and mutations do not necessarily affect how well the vaccine works
121 against the virus.

122 • Some vaccines against viral diseases remain effective many years after their development and
123 provide long-lasting protection, such as vaccines for measles or rubella.

124 • On the other hand, for diseases such as flu, virus strains change so often and to such an extent
125 that the vaccine composition must be updated on a yearly basis for it to be effective.

126 • The scientific community and regulators will monitor whether the coronavirus Sars-CoV-2 changes
127 over time and, if so, whether vaccines can protect people from infection with new variants.